Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070217 | 0.95 | PPARA (0.43) | PPARAMAPTSMN1; SMN2THRBPPARG | |
| SCHEMBL7067668 | 0.92 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL7068781 | 0.92 | PPARA (0.43) | PPARAMAPTSMN1; SMN2THRBPPARG | |
| SCHEMBL7070114 | 0.92 | NMT1 (0.42) | PPARAMAPTSMN1; SMN2THRBPPARG | |
| SCHEMBL7067961 | 0.91 | PPARA (0.43) | PPARAMAPTSMN1; SMN2THRBPPARG | |
| SCHEMBL7072403 | 0.91 | MAPT (0.45) | PPARAMAPTSMN1; SMN2THRBPPARG | |
| SCHEMBL7072415 | 0.90 | PPARA (0.42) | PPARAMAPTPPARGPPARDKMT2A | |
| SCHEMBL7070604 | 0.90 | MAPT (0.44) | MAPTSMN1; SMN2THRBLMNAKDM4E | |
| SCHEMBL7065932 | 0.90 | PPARA (0.41) | PPARAMAPTSMN1; SMN2THRBPPARG | |
| SCHEMBL7067700 | 0.89 | PPARA (0.41) | PPARAMAPTSMN1; SMN2THRBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PPARA 3/4885MAPT 2433/4885SMN1; SMN2 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.